MRX I

Drug Profile

MRX I

Alternative Names: MRX-I

Latest Information Update: 25 Oct 2016

Price : $50

At a glance

  • Originator MicuRx Pharmaceuticals
  • Class Anti-infectives; Antibacterials; Oxazolidinones
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Skin and soft tissue infections
  • No development reported Methicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant enterococcal infections

Most Recent Events

  • 21 Oct 2016 Phase-III clinical trials in Skin and soft tissue infections in China (PO)
  • 26 Sep 2016 MicuRx Pharmaceuticals plans to file a Chinese NDA for acute bacterial skin and skin structure infections in China
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Methicillin-resistant-Staphylococcus-aureus-infections(In volunteers) in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top